Novartis AG : Technically solid
Entry price | Target | Stop-loss | Potential |
---|
CHF 80.22 |
CHF 86 |
CHF 77.5 |
+7.21% |
---|
Shares in Novartis show a positive technical chart pattern over the medium term. The timing to jump back on the rising trend seems good.
Summary● The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
● In a short-term perspective, the company has interesting fundamentals.
Strengths● Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
● This company will be of major interest to investors in search of a high dividend stock.
● For the past twelve months, EPS forecast has been revised upwards.
● For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Weaknesses● According to forecast, a sluggish sales growth is expected for the next fiscal years.
● With an enterprise value anticipated at 3.95 times the sales for the current fiscal year, the company turns out to be overvalued.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.